Compare Repligen Corporation Common Stock (RGEN) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Zillow Group Inc Class A — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Zillow Group Inc Class A trades at $29.53 (market cap $6.33B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Zillow Group Inc Class A for 86 Days on average.
| RGEN | ZG | |
|---|---|---|
Market Cap | $11.14B | $6.33B |
Volume | 1,259,263 | 1,202,678 |
Sector | Health | Media |
52-Week High | $194.57 | $74.58 |
52-Week Low | $102.87 | $27.70 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $11.02B | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Zillow Group (ZG) trades at $29.27, up 2.02% today, amid a challenging housing market. The stock is technically bearish, trading near its pivot point of $29, with key resistance at $30 and support at $28. Fundamentally, the company has returned to profitability in 2025 with a net income of $23 million, a significant improvement from prior years' losses, though its P/E ratio of 125.43 remains high. Recent news highlights competitive pressures and interest rate sensitivity.
The outlook is mixed. Analyst consensus is a 'Hold' with a $48.60 price target, implying substantial upside, but execution on its integrated transaction platform and navigating housing affordability headwinds are key. Risks include market volatility and a high valuation. The path to sustained profitability will be the primary driver for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
